NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Dec. 2013 was $651 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $2,103 Mil.
This is the expense the company spent on research and development.
Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 464.185883997 (Mar. 2013 ) + 476.482976483 (Jun. 2013 ) + 511.342846689 (Sep. 2013 ) + 650.848695017 (Dec. 2013 ) = $2,103 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Novo Nordisk A/S Annual Data
|Research & Development||773||825||1,101||1,691||1,399||1,507||1,722||1,672||1,943||2,141|
Novo Nordisk A/S Quarterly Data
|Research & Development||417||478||443||423||455||572||464||476||511||651|